|Guideline Developer||Term and Definition|
|American Psychiatric Association||Substantial clinical confidence: Definition not provided in guideline.
Moderate clinical confidence: Definition not provided in guideline.
Guideline Workgroup and Guideline Steering Committee: The guideline was developed by a work group and under the direction of a steering committee.
|National Institute for Health and Clinical Excellence (for depression and anxiety)||Very low: Any estimate of effect is uncertain.
Low: Further research is very likely to have an important impact on our confidence in the estimate of the effect and is likely to change the estimate.
Moderate: Further research is likely to have an important impact on our confidence in the estimate of the effect and may change the estimate.
High: Further research is very unlikely to change our confidence in the estimate of the effect.
|National Institute for Health and Clinical Excellence (for PTSD)||Treatment shows clinically important benefits: At least one RCT as part of a body of literature of overall good quality and consistency addressing the specific recommendation without extrapolation.
Good practice point: Based on the clinical experience of the guideline development group.
|U.S. Department of Veteran Affairs/ U.S. Department of Defense||Strong recommendation to provide the treatment: Good evidence was found that the intervention improves important health outcomes and concludes that benefits substantially outweigh harm.
No recommendation for or against the routine provision of the treatment: At least fair evidence was found that the intervention can improve health outcomes, but concludes that the balance of benefits and harms is too close to justify a general recommendation.
|Australian Center for Post Traumatic Mental Health||Body of evidence can be trusted to guide practice: Grade A rating; no further definition provided.
This report was prepared under contract #HHSP2332010016WI between the U.S. Department of Health and Human Services (HHS), Office of Disability, Aging and Long-Term Care Policy (DALTCP) and Mathematica Policy Research. For additional information about this subject, you can visit the DALTCP home page at http://aspe.hhs.gov/office_specific/daltcp.cfm or contact the ASPE Project Officer, D.E.B. Potter, at HHS/ASPE/DALTCP, Room 424E, H.H. Humphrey Building, 200 Independence Avenue, S.W., Washington, D.C. 20201. His e-mail address is: D.E.B.Potter@hhs.gov.
To obtain a printed copy of these reports, send the full report title and your mailing information to:
U.S. Department of Health and Human Services
Office of Disability, Aging and Long-Term Care Policy
Room 424E, H.H. Humphrey Building
200 Independence Avenue, S.W.
Washington, D.C. 20201